Prevalence of Metabolic‐Associated Steatotic Liver Disease in Patients With Primary Aldosteronism
Authors' conclusion
Prevalence of MASLD was increased in PA (higher in uPA than BPA) compared to MACS and NFAI, and similar to adrenal CS.
Study context
- Population
- Patients with PA vs benign adrenal adenomas; hepatic steatosis by liver/spleen (L/S) ratio on unenhanced abdominal CT (reference <1.1)
- Participants
- 41 / 50 / 48 / 10
- Exposure
- PA vs nonfunctioning adrenal incidentalomas (NF-AI), mild autonomous cortisol secretion (MACS) and adrenal Cushing Syndrome (CS)
- PAn = 41
- NF-AIn = 50
- MACSn = 48
- CSn = 10
- Outcome
- Metabolic associated steatotic liver disease (MASLD) prevalence (hepatic steatosis by L/S ratio on unenhanced CT)
Methodological detailssingle-centre
- Single-centre
Main finding
As reported in the abstract
MASLD prevalence
- PA vs MACS: P < 0.05
- PA vs NF-AI: P < 0.001
- PA vs CS: P = 0.61
Observational data: associations, not effects.
Further findings
| Outcome | P value |
|---|---|
| L/S ratio at diagnosisPA vs NF-AI · 1.1 vs. 1.25; lower in PA | P < 0.001 |
| L/S ratio at diagnosisPA vs MACS · 1.1 vs. 1.21; lower in PA | p 0.007 |
| L/S ratio at diagnosisPA vs CS · 1.1 vs. 1.15; similar | P = 0.147 |
L/S ratio after medical or surgical treatment in PA
- Improvement in L/S ratio in PA patients, resulting in reduced liver steatosis
Original publication
Prevalence of Metabolic‐Associated Steatotic Liver Disease in Patients With Primary Aldosteronism. Clin Endocrinol (Oxf). Published 13 March 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →